CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...